Point-of-Care Coagulation Testing: Principles, Devices, and Clinical Applications

Overview

Point-of-care (POC) coagulation testing refers to haemostatic analysis performed outside the central laboratory - at or near the patient's bedside, in the operating theatre, intensive care unit, cardiac catheterisation laboratory, or emergency department. The primary goal is to provide clinically actionable results within minutes rather than the 45-90 minutes typical of central laboratory turnaround, enabling real-time therapeutic decision-making in time-critical situations such as massive haemorrhage, cardiac surgery, trauma, liver transplantation, and obstetric emergencies.

POC coagulation testing encompasses two broad categories: 1. Clot-based POC devices replicating conventional plasma-based screening tests (PT/INR, aPTT, ACT) on small whole-blood or plasma samples 2. Viscoelastic haemostatic assays (VHAs) - thromboelastography (TEG) and rotational thromboelastometry (ROTEM) - assessing the entire haemostatic process in whole blood under low-shear conditions, including clot formation, strength, and fibrinolysis

Classification of Point-of-Care Coagulation Devices

Principles of Operation

Conventional Clot-Based POC Devices (PT/INR, aPTT, ACT)

These instruments detect the mechanical or optical endpoint of fibrin clot formation using one of three principles:

• Mechanical (electromechanical): A probe or plunger detects increased viscosity as fibrin polymerises; movement ceases at clot endpoint (e.g., Hemochron)
• Optical (photometric): Change in light transmittance or turbidity is recorded as fibrin forms
• Dry chemistry cartridge: Reagents are lyophilised onto a disposable cartridge; a small whole-blood drop or plasma sample rehydrates the reagents and the device detects clot formation (e.g., CoaguChek, i-STAT)

The activated clotting time (ACT) uses contact activators (celite or kaolin) to initiate intrinsic pathway activation in native whole blood. It is the standard method for monitoring high-dose unfractionated heparin (UFH) during cardiopulmonary bypass (CPB) and percutaneous coronary intervention (PCI), where plasma aPTT is impractical.

Automated laboratory coagulation platforms operate on analogous principles - mechanical detection of fibrin formation, photometric recording of clot opacity, or rate of fibrin polymerisation - and are widely deployed for high-volume PT and aPTT testing in central laboratories. POC devices adapt these principles to small-volume, rapid-turnaround formats.

Viscoelastic Haemostatic Assays (VHAs)

VHAs measure the viscoelastic properties of an evolving whole-blood clot under low-shear conditions, capturing the transition from liquid blood to a formed, cross-linked clot and its subsequent fibrinolytic dissolution. They are primarily used as POC instruments in surgical settings; they are not standard diagnostic tools for evaluating coagulation abnormalities in the central haematology laboratory.

TEG (Thromboelastography): - A small blood sample is placed in a heated cup (37°C); a pin is suspended inside by a torsion wire - The cup oscillates; as clot forms and strengthens, it couples cup motion to the pin, increasing torque detected by the wire - The resulting trace is the classic thromboelastogram

ROTEM (Rotational Thromboelastometry): - The pin rotates rather than the cup; an optical detection system replaces the torsion wire - Less susceptible to mechanical vibration than TEG - better suited to busy surgical environments

Both platforms assess whole-blood coagulation including the contribution of platelets and coagulation factors, and results are available more rapidly than central laboratory testing. They are not directly interchangeable; institutional protocols must be validated for the specific platform in use.

Key Parameters of Viscoelastic Assays

TEG Parameters

ROTEM Parameters

ROTEM Assay Channels

Routine Coagulation Tests Relevant to POC Context

Standard coagulation screening tests - PT, aPTT, thrombin time (TT), and Clauss fibrinogen - underpin the interpretation framework into which POC results must be integrated.

Key aPTT interpretation points: - Prolonged aPTT + normal PT → deficiency of intrinsic pathway factors (VIII, IX, XI, XII, prekallikrein, HMWK) or inhibitors (lupus anticoagulant, heparin, factor VIII autoantibody) - Prolonged PT + normal aPTT → factor VII deficiency (extrinsic pathway) - Prolonged PT + prolonged aPTT → common pathway deficiency (X, V, II, fibrinogen), liver disease, DIC, vitamin K deficiency - Factor XII, HMWK, and prekallikrein deficiencies prolong aPTT but are not associated with clinical bleeding - Lupus anticoagulant prolongs aPTT but is associated with thrombosis risk, not bleeding - Elevated haematocrit (>55%) causes false prolongation of citrate-based tests - Direct oral anticoagulants (DOACs) have variable and unpredictable effects on aPTT

Mixing studies differentiate factor deficiency from inhibitors: addition of normal pooled plasma corrects a prolonged aPTT or PT due to factor deficiency. Failure to correct (or delayed prolongation after 2-hour incubation at 37°C) indicates an inhibitor. A factor VIII inhibitor characteristically requires incubation to demonstrate inhibition; lupus anticoagulant typically prolongs immediately without incubation.

Clinical Applications

Cardiac Surgery and Cardiopulmonary Bypass

CPB requires high-dose systemic heparinisation. ACT monitoring guides heparin dosing (target ACT typically >480 s during CPB, >300 s during PCI) and confirms adequate protamine reversal post-bypass. VHAs are used post-CPB to diagnose the cause of microvascular bleeding - distinguishing residual heparin (HEPTEM correction of INTEM CT), thrombocytopenia, hypofibrinogenaemia (low FIBTEM MCF), factor deficiency, and hyperfibrinolysis - enabling targeted product administration rather than empirical transfusion.

Trauma and Massive Haemorrhage

In trauma-associated coagulopathy (TAC), conventional laboratory results are delayed and may not accurately reflect the coagulation status of an actively bleeding patient. VHA-guided transfusion algorithms reduce red cell, FFP, and overall blood product use. TEG/ROTEM detect hyperfibrinolysis early - prompting urgent tranexamic acid administration (most effective within 3 hours of injury). FIBTEM MCF and A10 guide fibrinogen concentrate or cryoprecipitate use; MA/MCF guides platelet transfusion.

Liver Disease and Transplantation

Patients with cirrhosis have "rebalanced" haemostasis not adequately characterised by PT/INR alone. VHAs account for reduced anticoagulant proteins (protein C, protein S, antithrombin) alongside reduced pro-coagulant factors, providing a more complete picture of global haemostatic capacity. ROTEM and TEG guide blood product use during liver transplantation, where rapid-onset hyperfibrinolysis can be identified via the APTEM channel.

Obstetric Haemorrhage

Postpartum haemorrhage (PPH) is associated with rapid consumptive coagulopathy. FIBTEM MCF below 12 mm has been validated as an early predictor of severe PPH requiring fibrinogen supplementation. VHA results are available faster than conventional laboratory testing, supporting timely targeted therapy.

Monitoring Anticoagulant Therapy

Performance Characteristics and Analytical Considerations

Pre-analytical Variables

• Specimen collection: Citrated whole blood must be collected via clean venepuncture; line contamination with heparin or direct thrombin inhibitors causes spurious prolongation of clot-based tests
• Haematocrit: Elevated haematocrit (>55%) alters the plasma:citrate ratio, causing false prolongation of PT and aPTT. The citrate volume must be adjusted:

$$\text{Citrate volume (mL)} = \frac{1.85 \times 10^{-3} \times (100 - \text{Hct\%}) \times \text{Blood volume (mL)}}{100 - (100 - \text{Hct\%})}$$

• Temperature: VHAs are performed at 37°C; results may not reflect hypothermic in vivo conditions (relevant in trauma). Some platforms allow temperature adjustment.
• Timing: Whole-blood VHA samples should be run within 4 minutes of collection to avoid ex vivo activation; citrated samples are stable for 4 hours at room temperature before processing.
• Sample integrity: Clotted or haemolysed specimens invalidate results.

Analytical Variables

• Reagent variability: POC PT/INR devices use thromboplastin reagents with specific International Sensitivity Index (ISI) values; INR normalises for reagent variability in warfarin monitoring but is not validated for coagulopathy assessment in liver disease, DIC, or factor deficiencies
• Calibration: POC devices require regular calibration using liquid or electronic quality control materials; operator technique affects results on cartridge-based devices
• Interference: Elevated C-reactive protein falsely prolongs aPTT on some POC platforms; DOACs have variable and unpredictable effects on clot-based POC tests
• Non-interchangeability: TEG and ROTEM parameters are not directly interchangeable; institutional protocols must be validated for the specific platform in use
• Reference ranges: All coagulation test reference ranges are reagent- and instrument-dependent, requiring laboratory-specific and population-specific validation (e.g., aPTT is normally prolonged in the neonatal period)

Comparison with Central Laboratory Testing

Limitations of Point-of-Care Coagulation Testing

• VHAs assess haemostasis under low-shear, static conditions and do not replicate physiological shear-dependent platelet adhesion (vWF-mediated); they do not reliably detect mild platelet function disorders or von Willebrand disease
• Factor XIII cross-linking contributes to MA/MCF, but isolated factor XIII deficiency is not specifically identified by VHA (factor XIII deficiency is also not detected by PT or aPTT - specific factor XIII activity assays are required)
• POC INR is validated for stable anticoagulated patients on warfarin; it is not a substitute for laboratory INR in acute settings (anticoagulation reversal before emergency procedures, extremes of therapeutic range)
• Normal VHA results do not exclude all haemostatic defects - mild factor deficiencies may not be detected
• Global VHA assays, including thrombin generation tests, have not yet advanced from experimental research to routine clinical practice for most indications
• Quality assurance programmes for POC devices require dedicated governance frameworks; RCPA external quality assurance (EQA) programs exist for POC INR devices in Australia
• Operator training and competency documentation are mandatory; inadequately trained operators produce results with poor reproducibility

Integration into Clinical Algorithms

VHA-guided transfusion algorithms are embedded in major haemorrhage protocols for cardiac surgery, trauma, and liver transplantation. A representative decision framework:

Quality Assurance and Governance

POC testing programs must address:

• Operator training and competency assessment: All staff performing POC coagulation tests must undergo documented training and periodic competency review
• Internal quality control (IQC): Liquid or electronic controls must be run at defined intervals per manufacturer specifications and local laboratory policy
• External quality assurance (EQA): Participation in RCPA QAP POC programs (e.g., PT/INR) is required for accreditation
• Correlation with central laboratory: Periodic parallel testing between POC and central laboratory platforms is essential to identify systematic bias
• Connectivity and data management: POC results should be transmitted to the patient's electronic medical record; manual transcription introduces error
• Documentation of pre-analytical variables: Haematocrit, sample integrity, and timing of sample processing must be recorded
• Institutional protocols: Hospitals should have systems to respond rapidly to massive haemorrhage; laboratories should be geared to producing accelerated coagulation results, and transfusion committees should establish POC-integrated major haemorrhage protocols

Emerging and Future Technologies

• TEG 6s and ROTEM sigma: Fully automated, closed-cartridge systems that reduce operator variability; TEG 6s uses resonance-based detection rather than a torsion wire
• Platelet mapping (TEG): Uses specific activators (ADP, arachidonic acid) to assess platelet function contribution to clot strength - applicable to monitoring P2Y12 inhibitor and aspirin effect
• Microfluidic POC devices: Novel platforms integrating multiple haemostatic tests on a single chip, aiming for whole-blood, minimal-volume global haemostasis assessment at the bedside
• Thrombin generation assays (TGA): The calibrated automated thrombogram (CAT) measures thrombin generation in platelet-poor or platelet-rich plasma using automated fluorescence or chromogenic readouts; currently primarily a research tool but transitioning toward clinical utility in monitoring haemophilia treatment and thrombosis risk. These assays require centrifugation and are not yet true POC instruments.
• Clot waveform analysis: A derivative of automated aPTT analysis that detects the rate and pattern of fibrin polymerisation; used in some centres to detect DIC and hypercoagulable states

Key Points for Examination

• POC INR is validated for warfarin self-monitoring only - it is not valid for assessing coagulopathy in liver disease, DIC, or factor deficiencies; reference ranges for all coagulation tests are reagent- and instrument-dependent
• ACT is the standard POC method for monitoring high-dose UFH during CPB (target >480 s); protamine reversal is confirmed by return to baseline ACT
• ROTEM and TEG are not interchangeable; FIBTEM MCF isolates the fibrinogen contribution to clot strength; HEPTEM detects residual heparin by comparing INTEM CT with and without heparinase
• VHAs detect hyperfibrinolysis directly (elevated LY30 or ML), distinguishing it from other causes of coagulopathy and prompting tranexamic acid in trauma/surgical bleeding
• Factor XIII deficiency is not detected by PT, aPTT, or VHA - specific factor XIII activity assays are required
• Thrombin time is prolonged by heparin and dabigatran; reptilase time is not prolonged by heparin - comparing the two distinguishes heparin effect from dysfibrinogenaemia; derived fibrinogen assays should not be used
• Pre-analytical errors - line contamination with heparin, elevated haematocrit (>55%), delayed whole-blood testing, haemolysed or clotted specimens, and elevated CRP - are the most common causes of erroneous POC coagulation results
• All POC coagulation testing programs require operator competency documentation, IQC, EQA participation, and periodic correlation with the central laboratory